Effect of long-term treatment with enalapril in streptozotocin diabetic and DOCA hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 2, 1998, Pages 317-322

  Goyal, R K ^a,c   Satia, M C ^b   Bangaru, R A ^b   Gandhi, T P ^b  

^a L M COLLEGE OF PHARMACY   (India)

^b Cadila Pharmaceutical Ltd   (India)

^c ZYDUS RESEARCH CENTRE   (India)

Author keywords

Diabetes mellitus; DOCA; Enalapril; Hypertension; Streptozotocin

Indexed keywords

ENALAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HEART LEFT VENTRICLE FILLING PRESSURE; HEART RATE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOINSULINEMIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BODY WEIGHT; DESOXYCORTICOSTERONE; DIABETES MELLITUS, EXPERIMENTAL; ENALAPRIL; FEMALE; HYPERTENSION; LIPID METABOLISM; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, WISTAR; STREPTOZOCIN;

EID: 0031873953     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199808000-00021     Document Type: Article

References (28)

1. Fuller JH, Shipley MJ, Rose G, Jerrett RJ. Mortality from coronary disease and stroke in relation to degree of glycaemia: the Whitehall study. Br Med J 1983;287:867-73.
2. Panzaram G. mortality and survival in type 2 diabetes mellitus. Diabetologia 1987;30:123-31.
3. Kannel WB, McGee DL. Diabetes and cardiovascular disease. JAMA 1979;241:2035-8.
4. Factor SM, Minase T, Sonnenblick EH. Clinical and morphological features of human hypertensive diabetic cardiomyopathy, Am Heart J 1980;99:446-56.
5. Rodrigues B, Goyal RK, McNeill JH. Effects of hydralazine on STZ induced diabetic rats - prevention of hyperlipidaemia and improvement in cardiac function. J Pharmacol Exp Ther 1986;237:299-307.
6. Bangaru RA, Lakkad NB, Goyal RK, Effect of chronic atenolol treatment on diabetes induced cardiac depression and other complications. Ind J Physiol Pharmacol 1996;40:220-4.
7. Shah TS, Satia MC, Bangaru RA, Gandhi TP, Goyal RK. Effect of chronic treatment with nifedipine on diabetes induced cardiac dysfunction and other complication. J Cardiovasc Pharmacol 1995;26:6-12.
8. Amery AL, Bulpiti C, DeSchaepdryver A, et al. Glucose intolerance during diabetic therapy: results of trial by the European Working Party on hypertension in the elderly. Lancet 1978;1:681-3.
9. Malini PL, Strocchi E, Ambrosiani E, Magnani B. Long term anti-hypertensive, metabolic and cellular effects of enalapril. J Hypertens 1984;2(suppl 2):101-5.
10. Fraser AG, Henderson AH, Lewis MJ, Mulligan IP, Tirlapur VG. Acute and chronic effects of enalapril during rest and exercise in congestive heart failure. Br J Clin Pharmacol 1985;20:263-4.
11. Baba T, Ishizaki T, Recent advances in pharmacological management of hypertension in diabetic patients with nephropathy: effects of antihypertensive drugs on kidney function and insulin sensitivity. Drugs 1992;43:464-89.
12. Johnson CL, Mooser V, Sun Y, Fabris ES. Changes in cardiac converting enzyme after myocardial infarction and hypertrophy in rats. Clin Exp Pharmacol Physiol 1991;18:107-10.
13. Hebden RA, Todd ME, Tang C, Gowen B, McNeill JH. Association of DOCA hypertension with induction of atherosclerosis in rats with short term diabetes mellitus. Am J Physiol 1990;258:R1042-50.
14. Gavras H, Brunner HR, Laragh JH, Vaughan ED Jr, Koss M, Cote LJ. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res 1975;36:300-9.
15. Schenk J, McNeill JH. The pathogenesis of DOCA-salt hypertension. J Pharmacol Methods 1992;27:161-70.
16. Wada T, Kanagawa R, Ishimaro Y, Inada Y, Nishikawa K. Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate salt hypertensive rats. J Hypertens 1995;13:113-22.
17. Dai S, McNeill JH. Myocardial performance of STZ-diabetic DOCA hypertensive rats. Am J Physiol 1992;263:H1798-805.
18. Ramos OL. Diabetes mellitus and hypertension: state of the art lecture. Hypertension 1988;11 (suppl 1):114-8.
19. Ueno Y, Mohara O, Brosnihan KB, Ferrario CM. Characteristics of hormonal and neurogenic mechanisms of DOCA-induced hypertension. Hypertension 1988;11(suppl II):172-7.
20. Zicha J, Kunes J, Lebl M, Pohlova I, Slaninova J, Jelinek J. Antidiuretic and presser actions of vasopressin in age-dependent DOCA-salt hypertension. Am J Physiol 1989;256:138-45.
21. Savaress JJ, Berkowitz BA, Beta adrenoreceptors in diabetic rat heart. Life Sci 1979;25:2075-8.
22. Chatelaine RE. Elevated arterial cyclic AMP levels during the onset of renal hypertension in rats. Clin Sci 1983;64:355-8.
23. Dowel RT, Atkins FL, Love S. Integrative nature of time course of cardiovascular alterations in the diabetic rats. J Cardiovasc Pharmacol 1986;8:406-13.
24. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1987;79:1-6.
25. Dzau VJ. Vascular angiotensin pathways: new therapeutic target. J Cardiovasc Pharmacol 1987;10(suppl 7):S9-16.
26. Dzau VJ, Re RN. Evidence for the existence of renin in heart. Circulation 1987;73(suppl I):1134-6.
27. Schunkert H, Dazu VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: effects on coronary resistance, contractility and relaxation. Clin Invest 1990;86:1913-20.
28. Kromer EP, Elsner D, Riegger GAJ. Role of neurohumoral systems for pressure induced left ventricular hypertrophy in experimental supravalvular aortic in rats. Am J Hyperten 1991;4:521-4.